CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 4 indication-specific expa...
Phase 1, Phase 2
Palo Alto, California, United States and 56 other locations
the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia...
Phase 1
Palo Alto, California, United States
The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...
Phase 2, Phase 3
Palo Alto, California, United States and 7 other locations
in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...
Phase 1, Phase 2
Palo Alto, California, United States and 33 other locations
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Par...
Phase 1
Palo Alto, California, United States and 10 other locations
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation...
Phase 3
Stanford, California, United States and 6 other locations
chemotherapy in induction-eligible patients with acute myeloid leukemia.This study involves the following:* Venetoclax and azacitidine (inve...
Phase 2
Palo Alto, California, United States and 8 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Oakland, California, United States and 43 other locations
in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related a....
Phase 2
San Francisco, California, United States and 3 other locations
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't r...
Phase 1
Palo Alto, California, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal